|5.05||-0.0800||-1.56%||Vol 938.93K||1Y Perf 68.27%|
|Apr 9th, 2021 16:00 DELAYED|
|- -||-0.03 -0.59%|
|Target Price||9.25||Analyst Rating||Moderate Buy 2.00|
|Potential %||83.17||Finscreener Ranking||★★★ 49.89|
|Insiders Trans % 3/6/12 mo.||-100/-69/-53||Value Ranking||★★★+ 55.14|
|Insiders Value % 3/6/12 mo.||-100/-8/-4||Growth Ranking||★★+ 49.78|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/75/74||Income Ranking||— -|
|Market Cap||785.11M||Earnings Rating||Strong Sell|
|Price Range Ratio 52W %||20.25||Earnings Date||13th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||13th May 2021|
|Estimated EPS Next Report||-0.25|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||723.42K|
|Avg. Monthly Volume||820.71K|
|Avg. Quarterly Volume||960.60K|
Adaptimmune Therapeutics plc (NASDAQ: ADAP) stock closed at 5.05 per share at the end of the most recent trading day (a -1.56% change compared to the prior day closing price) with a volume of 939.75K shares and market capitalization of 785.11M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 462 people. Adaptimmune Therapeutics plc CEO is Adrian Rawcliffe.
The one-year performance of Adaptimmune Therapeutics plc stock is 68.27%, while year-to-date (YTD) performance is -6.31%. ADAP stock has a five-year performance of -48.57%. Its 52-week range is between 2.93 and 13.4, which gives ADAP stock a 52-week price range ratio of 20.25%
Adaptimmune Therapeutics plc currently has a PE ratio of -5.50, a price-to-book (PB) ratio of 2.41, a price-to-sale (PS) ratio of 272.81, a price to cashflow ratio of 30.40, a PEG ratio of 2.32, a ROA of -40.10%, a ROC of -44.18% and a ROE of -54.68%. The company’s profit margin is -%, its EBITDA margin is -3 715.00%, and its revenue ttm is $3.20 Million , which makes it $0.02 revenue per share.
Of the last four earnings reports from Adaptimmune Therapeutics plc, there were 0 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. Adaptimmune Therapeutics plc’s next earnings report date is 13th May 2021.
The consensus rating of Wall Street analysts for Adaptimmune Therapeutics plc is Moderate Buy (2), with a target price of $9.25, which is +83.17% compared to the current price. The earnings rating for Adaptimmune Therapeutics plc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Adaptimmune Therapeutics plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Adaptimmune Therapeutics plc has a Sell technical analysis rating based on Technical Indicators (ADX : 16.80, ATR14 : 0.51, CCI20 : -90.51, Chaikin Money Flow : -0.24, MACD : -0.22, Money Flow Index : 42.36, ROC : -13.07, RSI : 43.53, STOCH (14,3) : 39.60, STOCH RSI : 0.85, UO : 47.29, Williams %R : -60.40), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Adaptimmune Therapeutics plc in the last 12-months were: Adrian Rawcliffe (Sold 20 341 shares of value $124 916 ), Elliot Norry (Sold 3 797 shares of value $21 644 ), Gavin Hilary James Wood (Buy at a value of $70 010), Helen Tayton-Martin (Option Excercise at a value of $280 245), John Lunger (Sold 11 304 shares of value $81 504 ), Lawrence M. Alleva (Buy at a value of $24 381), William C. Bertrand (Buy at a value of $143 824), William C. Bertrand (Sold 5 733 shares of value $32 386 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.